aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
The presentation will be available for on-demand access starting
Company management will also participate in virtual one-on-one meetings with registered attendees of the partnering system hosted by the
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.
Director, Investor Relations and Corporate Communications
Source: aTyr Pharma, Inc.